Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55’s Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

Thursday, June 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported new preclinical data for Mira-55, highlighting its unique pharmacological mechanism that does not induce central nervous system effects like THC. The data also indicate that Mira-55 exhibits anxiolytic activity, a benefit not associated with THC, reinforcing its potential for treating chronic inflammatory pain. This development supports ongoing research and clinical trials.
Price reaction · baseline $0.9104 (2026-06-24 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Mira-55 shows differentiated mechanism of action compared to THC.
  • Demonstrates anxiolytic activity, which THC does not provide.
  • Supports continued development for chronic inflammatory pain.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Data show Mira-55 does not produce the central nervous system effects associated with THC and acts through a distinct pharmacological mechanism, while demonstrating anxiolytic activity, which THC does not produce, supporting continued development for chronic inflammatory pain MIAMI, FL / ACCESS Newswire / June 25, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”) , a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiat…
You can read the full content here

Frequently Asked Questions

What is Mira-55?

Mira-55 is a novel therapy developed by MIRA Pharmaceuticals for chronic inflammatory pain.

How does Mira-55 differ from THC?

Mira-55 does not produce central nervous system effects and has a distinct pharmacological mechanism.

What activity does Mira-55 demonstrate?

Mira-55 shows anxiolytic activity, which THC does not provide.

What is the significance of the new data?

The data supports the continued development of Mira-55 for treating chronic inflammatory pain.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals Mira-55 THC anxiolytic activity chronic inflammatory pain
Last updated: Jun 25, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →